This message contains images. If you don't see images, click here to view.
Advertise in this news brief.
|
|
| |
Advertisement
Health plans' success mixed in managing cancer care programs
Managed Care
Cancer is a major service line for most hospitals. It is one of the largest revenue producers, and it is seen as a growth opportunity as the number of cancer diagnoses continues to increase in an aging population. The National Cancer Institute says there will be more than 1.6 million new cancer cases this year and the volume will consistently grow by 4 percent for years ahead. The average cost of a cancer episode may be as high as $102,000, according to data from an oncology ACO program sponsored by Florida Blue.
|
|
Share this article:
    |
|
|
Advertisement
Prostate cancer recurrence risk tied to lipid levels
The New York Times
Abnormal lipid levels are associated with an increased risk for recurrence of prostate cancer, researchers report.
There is no evidence for an association of lipid levels with prostate cancer, but there is some mixed evidence for their link to aggressive cancers and to the recurrence of cancer. The study examined the impact of lipid levels on the risk for recurrence in 843 men who were not using statins before the surgical removal of their cancerous prostate glands.
Good news for young patients with a leukemia subtype with poor prognosis
Oncology Nurse Advisor
Adjusting treatment based on early response to chemotherapy made a life-saving difference to young patients with an acute lymphoblastic leukemia (ALL) subtype, according to a new study whose results are good news for children and adolescents with Philadelphia chromosome-like ALL (Ph-like ALL), a subtype that until now was associated with a poor prognosis. Ph-like ALL accounts for as much as 15 percent of cases of the most common pediatric cancer, B-ALL, which affects the B lymphocytes.
Advertisement
FDA approves Akynzeo for chemotherapy-induced nausea, vomiting
HemOnc Today
The FDA announced the approval of Akynzeo to alleviate nausea and vomiting in patients with cancer who are undergoing chemotherapy. Akynzeo — a fixed combination capsule composed of palonosetron (Aloxi; Eisai, Helsinn Healthcare) and netupitant (Eisai, Helsinn Healthcare) — is designed to treat nausea and vomiting during the acute and delayed phases after chemotherapy administration.
Early Bird fee ends today — Pursuing Excellence through NAPBC Accreditation
NAPBC
Whether you are preparing for a re-accreditation survey, first survey, or looking for information
on the National Accreditation Program for Breast Centers (NAPBC), this education program gives you the information you need. Avoid the fee increase; register today.
Pursuing Excellence through NAPBC Accreditation is the only education program developed
and taught by NAPBC staff, board members, and surveyors. This program prepares your breast
center for survey and helps staff not familiar with the NAPBC standards understand their role in
the accreditation process.
Advertisement
PRODUCT SHOWCASE
 |
|
NCBC allows members to have access to, not 2 or 3 certifications, but 4 nationally recognized certification programs! For more information about the NQMBC, Navigator, Clinical Breast Examiner, and Breast Self-Exam certification programs, visit our website at www.breastcare.org.
FNQMBC
CBE
Navigator
|
|
Landscape analysis reveals how little is known, or said, about metastatic breast cancer
Forbes
The Metastatic Breast Cancer Alliance recently put forth a landscape analysis on the needs of patients with metastatic breast cancer (MBC). This report follows and refers to a recent, Pfizer-backed survey of 2,090 men and women, which revealed major deficiencies in common knowledge about the condition. Among U.S. adults surveyed in April 2014, 72 percent (mistakenly) believe that advanced breast cancer is curable if detected early. Half of the respondents suggested that people living with metastatic disease have it because they didn’t take appropriate treatment or preventive measures. As summarized in the larger report, more than 60 percent said they knew “little or nothing” about metastatic breast cancer.
Missed last week's issue? See which articles your colleagues read most.
Rare cancer recoveries could be key to wider treatments
The Boston Globe
For years, they have been among modern medicine’s most arresting fables: A 54-year-old woman sees her tumors melt away in a clinical trial, but no one else with the same lethal thyroid cancer responds. An elderly man with advanced bladder cancer enrolls in a safety study of two therapies and is the one person to see his cancer vanish for over a year. A drug flops in a clinical trial but works for a 73-year-old woman with bladder cancer who is still alive five years later. Physicians have traditionally viewed the rare cancer patients who bounce back from near-certain death as inspiring anecdotes, not science.
Two experts discuss mammography issues on The Recovery Room Show
NAPBC
The Recovery Room Show recently launched a new episode discussing the benefits and controversies surrounding mammographic screening. In the episode, host Frederick L. Greene, MD, FACS, a surgical oncologist from Charlotte, N.C., and a member of the Commission on Cancer since 2000, talks with two leading experts in the field. The show includes a discussion on common concerns with mammography, the role of insurance companies, MRIs, and a high-profile recent Canadian study that cast doubt on the abilities of the screening tool.
Hyperbaric oxygen therapy to relieve post-radiation therapy effects
Radiation Therapy News
Oxygen, a simple molecule surrounding us in daily life, is becoming a mainstream treatment following radiation therapy. Patients who have undergone radiation therapy can experience benefits of breathing 100% oxygen at pressures greater than atmospheric. This treatment is known as hyperbaric oxygen and is indicated to treat a handful of existing disease conditions.
Lung cancer genes reveal risks of even short-term smoking
Healthline
Why is lung cancer so tough to beat? And why do many people relapse after surgery to remove lung tumors? Recent research published in the journal Science focused on these two questions. Lung cancer will kill 159,000 people this year alone, according to the American Cancer Society.
Important webinar — Caring for patients' spiritual needs: Resources for all providers
American Psychosocial Oncology Society
Plan now to join this webinar on Oct. 24, 2014, from 2:30 to 4:00 pm Eastern Time to participate in a program that will discuss the nature of religiosity/spirituality (R/S) in cancer care, strategies for initiating conversations about patients’ R/S, and strategies for effective collaboration with health care chaplains. The webinar is intended for providers in all disciplines with varying degrees of experience in caring for patients with spiritual needs. For detailed information, contact the American Psychosocial Oncology Society (APOS) Headquarters.
|
|
|
Advertisement
|
|
|
The CoC Brief
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit
Samantha Emerson, Content Editor, 469.420.2669
Contribute news
Disclaimer: The CoC Brief is a digest of the most important news selected for the American College of Surgeons Commission on Cancer from thousands of sources by the editors of MultiBriefs, an independent organization that also manages and sells advertising. The Commission on Cancer does not endorse any of the advertised products and services. Opinions expressed in the articles are those of the author and not of the American College of Surgeons and the Commission on Cancer.
Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.
This edition of The CoC Brief was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!
|
|
Recent issues
Oct. 8, 2014
Oct. 1, 2014
Sept. 24, 2014
Sept. 17, 2014
|
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
